Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Clinical trial NCT05013216 · RECRUITING
Trial details
- NCT number
- NCT05013216
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-11
- Primary completion
- 2027-10-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.